C3 and neoplasm: C3a via C3aR also inhibits NK cell cytotoxicity (213). C3aR activation also blocks NK cell migration to the tumor microenvironment by altering localization and confirmation of lymphocyte function-associated antigen-1 (LFA-1) (214, 215).